Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction

NCT03470441 is registered in ClinicalTrials.gov with Faraday Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03470441
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03470441 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction
Lead sponsor
Faraday Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 27, 2017
Completion date
January 3, 2019
Enrollment
120 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction, stemi